Top

Current Hepatology Reports

Published in:

01-12-2018 | Hepatic Cancer (A Singal and A Mufti, Section Editors)

Indications and Best Practices for Intra-arterial Therapies to Treat Hepatocellular Carcinoma

Authors: Michael Hsu, Muneeb Ahmed, Ammar Sarwar

Published in: Current Hepatology Reports | Issue 4/2018

Abstract

Purpose of Review

The purpose of this review is to re-evaluate the role of intra-arterial therapies for hepatocellular carcinoma (HCC) recommended by contemporary staging systems.

Recent Findings

Currently, intra-arterial therapies are recommended by the Barcelona Clinic Liver Cancer (BCLC) staging system only for patients with BCLC B HCC in the form of trans-arterial chemoembolization. Recently, randomized controlled trials in patients with BCLC C HCC without metastatic disease have suggested a potential role for trans-arterial radioembolization (TARE) with fewer adverse events and better quality of life compared to sorafenib. Randomized controlled trials have also demonstrated the benefit of using combination therapy of trans-arterial chemoembolization (TACE) with ablation for patients with BCLC A HCC [single tumors (3–7 cm)] compared to ablation alone. Finally, promising results from single-center studies indicate that TARE using a radiation segmentectomy technique may be a potentially curative therapy for tumors less than 3 cm, supporting its use in patients with BCLC A HCC that are not amenable to surgical or ablative therapies.

Summary

Recent randomized clinical trials have demonstrated the benefit of intra-arterial therapies in subpopulations of BCLC stages A, B, and C. These studies highlight the need for careful patient assessment, staging, and multidisciplinary discussion to consider treatments that are not currently included in guidelines but can improve patient outcomes for HCC.

Wang H, Naghavi M, Allen C, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459–544.

Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer. 2016;139(7):1534–45.PubMedPubMedCentral

• Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–38 This is the original description of BCLC classification, which is very helpful in stratifying patients with HCC by prognosis and optimal treatment modality.PubMed

Marrero JA, Kulik LM, Sirlin C, et al. Diagnosis, staging and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatol Baltim Md 2018;

Kim BK, Kim SU, Park JY, et al. Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma. Liver Int. 2012;32(7):1120–7.PubMed

Marrero JA, Kudo M, Bronowicki J-P. The challenge of prognosis and staging for hepatocellular carcinoma. Oncologist. 2010;15(Suppl 4):23–33.PubMed

Sangiovanni A, Colombo M. Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int. 2016;36(S1):124–9.PubMed

Kalyan A, Kulik L. Multidisciplinary care in hepatocellular carcinoma: where do we go from here? Gastroenterology. 2017;152(8):1823–5.PubMed

• Serper M, Taddei TH, Mehta R, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology. 2017;152(8):1954–64 This study highlights the value of multi-disciplinary care for HCC treatment.PubMedPubMedCentral

10.

Holliday EB, Allen PK, Elhalawani H, Abdel-Rahman O. Treatment at a high-volume centre is associated with improved survival among patients with non-metastatic hepatocellular carcinoma. Liver Int Off J Int Assoc Study Liver. 2018;38(4):665–75.

11.

Song MJ. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. World J Gastroenterol WJG. 2015;21(13):3843–9.PubMed

12.

Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–42.PubMed

13.

Facciorusso A, Bellanti F, Villani R, et al. Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials. United Eur Gastroenterol J. 2017;5(4):511–8.

14.

Park J-W, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–66.PubMedPubMedCentral

15.

de Baere T, Arai Y, Lencioni R, et al. Treatment of liver tumors with lipiodol TACE: technical recommendations from experts opinion. Cardiovasc Intervent Radiol. 2016;39(3):334–43.PubMed

16.

Ji SK, Cho YK, Ahn YS, et al. Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization. Korean J Radiol. 2008;9(6):534–40.PubMedPubMedCentral

17.

Forner A, Ayuso C, Varela M, et al. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer. 2009;115:616–23.PubMed

18.

Gillmore R, Stuart S, Kirkwood A, et al. EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization. J Hepatol. 2011;55(6):1309–16.PubMed

19.

Riaz A, Miller FH, Kulik LM, et al. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. JAMA. 2010;303(11):1062–9.PubMedPubMedCentral

20.

• Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550–8 This study demonstrates the use of the ALBI grade to prognosticate patients with HCC.PubMed

21.

Hickey R, Mouli S, Kulik L, et al. Independent analysis of albumin-bilirubin grade in a 765-patient cohort treated with transarterial locoregional therapy for hepatocellular carcinoma. J Vasc Interv Radiol. 2016;27:795–802.PubMed

22.

Roayaie S. PALBI-an objective score based on platelets, albumin & bilirubin stratifies HCC patients undergoing resection & ablation better than child’s classification. 2015.

23.

Liu PH, Hsu CY, Hsia CY, et al. ALBI and PALBI grade predict survival for HCC across treatment modalities and BCLC stages in the MELD Era. J Gastroenterol Hepatol. 2017;32:879–86.PubMed

24.

Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649–55.PubMed

25.

Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatol Baltim Md. 2010;52(2):762–73.

26.

Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.PubMed

27.

Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71.PubMed

28.

Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474–81.PubMed

29.

Lencioni R, de Baere T, Burrel M, et al. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Interv Radiol. 2012;35:980–5.

30.

• Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol. 2010;33:41–52 This study is one of the seminal RCT of conventional vs. DEB TACE, which demonstrated no survival benefit of DEB-TACE compared to conventional TACE.

31.

Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255–64.PubMedPubMedCentral

32.

Facciorusso A, Di Maso M, Muscatiello N. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: a meta-analysis. Dig Liver Dis. 2016;48:571–7.PubMed

33.

Lee KH, Liapi E, Vossen JA, et al. Distribution of iron oxide-containing embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol. 2008;19:1490–6.PubMedPubMedCentral

34.

Dreher MR, Sharma KV, Woods DL, et al. Radiopaque drug-eluting beads for transcatheter embolotherapy: experimental study of drug penetration and coverage in swine. J Vasc Interv Radiol 2012;23:257–64 e4.

35.

Malagari K, Pomoni M, Moschouris H, et al. Chemoembolization of hepatocellular carcinoma with HepaSphere 30-60 mum. Safety and efficacy study. Cardiovasc Interv Radiol. 2014;37:165–75.

36.

Aliberti C, Carandina R, Lonardi S, et al. Transarterial chemoembolization with small drug-eluting beads in patients with hepatocellular carcinoma: experience from a cohort of 421 patients at an Italian center. J Vasc Interv Radiol. 2017;28:1495–502.PubMed

37.

Kettenbach J, Stadler A, Katzler IV, et al. Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Interv Radiol. 2008;31:468–76.

38.

Aliberti C, Carandina R, Sarti D, et al. Chemoembolization adopting polyethylene glycol drug-eluting embolics loaded with doxorubicin for the treatment of hepatocellular carcinoma. AJR Am J Roentgenol. 2017;209:430–4.PubMed

39.

Duan F, Wang EQ, Lam MG, et al. Superselective chemoembolization of HCC: comparison of short-term safety and efficacy between drug-eluting LC beads, quadraspheres, and conventional ethiodized oil emulsion. Radiology. 2016;278:612–21.PubMed

40.

Levy EB, Krishnasamy VP, Lewis AL, et al. First human experience with directly image-able iodinated embolization microbeads. Cardiovasc Interv Radiol. 2016;39:1177–86.

41.

Richter G, Radeleff B, Stroszczynski C, et al. Safety and feasibility of chemoembolization with doxorubicin-loaded small calibrated microspheres in patients with hepatocellular carcinoma: results of the MIRACLE I prospective multicenter study. Cardiovasc Interv Radiol. 2018;41:587–93.

42.

Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology. 2016;64:106–16.PubMed

43.

Sahara S, Kawai N, Sato M, et al. Prospective comparison of transcatheter arterial chemoembolization with lipiodol-epirubicin and lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma. Jpn J Radiol. 2010;28:362–8.PubMed

44.

Ikeda M, Kudo M, Aikata H, et al. Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial. J Gastroenterol. 2018;53:281–90.PubMed

45.

Kubota K, Hidaka H, Nakazawa T, et al. Prospective, randomized, controlled study of the efficacy of transcatheter arterial chemoembolization with miriplatin for hepatocellular carcinoma. Hepatol Res. 2018;48:E98–E106.PubMed

46.

Shi M, Lu LG, Fang WQ, et al. Roles played by chemolipiodolization and embolization in chemoembolization for hepatocellular carcinoma: single-blind, randomized trial. J Natl Cancer Inst. 2013;105:59–68.PubMed

47.

Liu B, Huang JW, Li Y, et al. Single-agent versus combination doxorubicin-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a single-blind, randomized, phase II trial. Oncology. 2015;89:23–30.PubMed

48.

Gomes AS, Monteleone PA, Sayre JW, et al. Comparison of triple-drug transcatheter arterial chemoembolization (TACE) with single-drug TACE using doxorubicin-eluting beads: long-term survival in 313 patients. AJR Am J Roentgenol. 2017;209:722–32.PubMed

49.

Sahara S, Kawai N, Sato M, et al. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. Cardiovasc Interv Radiol. 2012;35:1363–71.

50.

Yang H, Seon J, Sung PS, et al. Dexamethasone prophylaxis to alleviate postembolization syndrome after transarterial chemoembolization for hepatocellular carcinoma: a randomized, double-blinded, placebo-controlled study. J Vasc Interv Radiol 2017;28:1503–1511 e2.

51.

Ogasawara S, Chiba T, Ooka Y, et al. A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization. Hepatology. 2017.

52.

Padia SA, Lewandowski RJ, Johnson GE, et al. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol JVIR. 2017;28(1):1–15.PubMed

53.

Srinivas SM, Nasr EC, Kunam VK, Bullen JA, Purysko AS. Administered activity and outcomes of glass versus resin 90Y microsphere radioembolization in patients with colorectal liver metastases. J Gastrointest Oncol. 2016;7(4):530–9.PubMedPubMedCentral

54.

Lau W-Y, Kennedy AS, Kim YH, et al. Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2012;82(1):401–7.PubMed

55.

Garin E, Lenoir L, Edeline J, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40(7):1057–68.PubMedPubMedCentral

56.

Biederman DM, Titano JJ, Tabori NE, et al. Outcomes of radioembolization in the treatment of hepatocellular carcinoma with portal vein invasion: resin versus glass microspheres. J Vasc Interv Radiol. 2016;27(6):812–821.e2.PubMed

57.

Van Der Gucht A, Jreige M, Denys A, et al. Resin versus glass microspheres for 90Y transarterial radioembolization: comparing survival in unresectable hepatocellular carcinoma using pretreatment partition model dosimetry. J Nucl Med Off Publ Soc Nucl Med. 2017;58(8):1334–40.

58.

Kallini JR, Gabr A, Thorlund K, et al. Comparison of the adverse event profile of TheraSphere® with SIR-Spheres® for the treatment of unresectable hepatocellular carcinoma: a systematic review. Cardiovasc Intervent Radiol. 2017;40(7):1033–43.PubMed

59.

Weinstein JL, Ahmed M. Percutaneous ablation for hepatocellular carcinoma. AJR Am J Roentgenol. 2018;210(6):1368–75.PubMed

60.

•• Peng Z-W, Zhang Y-J, Liang H-H, Lin X-J, Guo R-P, Chen M-S. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology. 2012;262(2):689–700 This RCT of TACE-ablate approach for 3–5 cm HCC demonstrated superior survival by using this approach.PubMed

61.

Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010;116(23):5452–60.PubMed

62.

•• Peng Z-W, Zhang Y-J, Chen M-S, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(4):426–32 This RCT of TACE-ablate approach for 3–5 cm HCC demonstrated superior survival by using this approach.

63.

Bruix J, Takayama T, Mazzaferro V, et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2015;16(13):1344–54.PubMed

64.

Liao M, Zhu Z, Wang H, Huang J. Adjuvant transarterial chemoembolization for patients after curative resection of hepatocellular carcinoma: a meta-analysis. Scand J Gastroenterol. 2017;52:624–34.PubMed

65.

Wang Z, Ren Z, Chen Y, et al. Adjuvant transarterial chemoembolization for HBV-related hepatocellular carcinoma after resection: a randomized controlled study. Clin Cancer Res. 2018.

66.

van Lienden KP, van den Esschert JW, de Graaf W, et al. Portal vein embolization before liver resection: a systematic review. Cardiovasc Intervent Radiol. 2013;36(1):25–34.PubMed

67.

Lewandowski RJ, Donahue L, Chokechanachaisakul A, et al. (90) Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol. 2016;114(1):99–105.PubMed

68.

Riaz A, Gates VL, Atassi B, et al. Radiation segmentectomy: a novel approach to increase safety and efficacy of radioembolization. Int J Radiat Oncol Biol Phys. 2011;79(1):163–71.PubMed

69.

Biederman DM, Titano JJ, Bishay VL, et al. Radiation segmentectomy versus TACE combined with microwave ablation for unresectable solitary hepatocellular carcinoma up to 3 cm: a propensity score matching study. Radiology. 2017;283(3):895–905.PubMed

70.

Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatol Baltim Md. 2014;60(1):192–201.

71.

• Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation segmentectomy: potential curative therapy for early hepatocellular carcinoma. Radiology. 2018;171768 This is a description of a new technique for TARE for small HCC that may be potentially curative.

72.

Sofocleous CT, Boas FE. Radiation segmentectomy for hepatocellular carcinoma: ready for prime time? Radiology. 2018;180163.

73.

Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatol Baltim Md. 2018;67(1):358–80.

74.

Yin X, Zhang L, Wang YH, et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma. BMC Cancer. 2014;14:849.PubMedPubMedCentral

75.

Hirooka M, Hiraoka A, Ochi H, et al. Transcatheter arterial chemoembolization with or without radiofrequency ablation: outcomes in patients with Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma. AJR Am J Roentgenol. 2018;210:891–8.PubMed

76.

Fu Y, Zhao X, Yun Q, et al. Transarterial chemoembolization (TACE) plus percutaneous ethanol injection (PEI) for the treatment of unresectable hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8:10388–400.PubMedPubMedCentral

77.

Erhardt A, Kolligs F, Dollinger M, et al. TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. Cancer Chemother Pharmacol. 2014;74:947–54.PubMed

78.

Chao Y, Chung YH, Han G, et al. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer. 2015;136:1458–67.PubMed

79.

Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011;29:3960–7.PubMedPubMedCentral

80.

Sansonno D, Lauletta G, Russi S, Conteduca V, Sansonno L, Dammacco F. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist. 2012;17:359–66.PubMedPubMedCentral

81.

Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117–27.PubMed

82.

Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol. 2016;64:1090–8.PubMed

83.

Tong AKT, Kao YH, Too CW, Chin KFW, Ng DCE, Chow PKH. Yttrium-90 hepatic radioembolization: clinical review and current techniques in interventional radiology and personalized dosimetry. Br J Radiol. 2016;89(1062):20150943.PubMedPubMedCentral

84.

Pitton MB, Kloeckner R, Ruckes C, et al. Randomized comparison of selective internal radiotherapy (SIRT) versus drug-eluting bead transarterial chemoembolization (DEB-TACE) for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2015;38(2):352–60.PubMed

85.

Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497–507.e2.PubMed

86.

Zhang Y, Li Y, Ji H, Zhao X, Lu H. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: a meta-analysis. Biosci Trends. 2015;9(5):289–98.PubMed

87.

Facciorusso A, Serviddio G, Muscatiello N. Transarterial radioembolization vs chemoembolization for hepatocarcinoma patients: a systematic review and meta-analysis. World J Hepatol. 2016;8(18):770–8.PubMedPubMedCentral

88.

Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.PubMed

89.

Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25–34.PubMed

90.

Sinn DH, Cho J-Y, Gwak G-Y, et al. Different survival of Barcelona Clinic Liver Cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread. PLoS One. 2015;10(4):e0124434.PubMedPubMedCentral

91.

Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology. 2011;258:627–34.PubMed

92.

Choi GH, Shim JH, Kim MJ, et al. Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses. Radiology. 2013;269:603–11.PubMed

93.

Zhang Y, Fan W, Wang Y, et al. Sorafenib with and without transarterial chemoembolization for advanced hepatocellular carcinoma with main portal vein tumor thrombosis: a retrospective analysis. Oncologist. 2015;20:1417–24.PubMedPubMedCentral

94.

Geschwind JF, Kudo M, Marrero JA, et al. TACE treatment in patients with sorafenib-treated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON. Radiology. 2016;279:630–40.PubMed

95.

Finn RS, Zhu AX, Farah W, et al. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis. Hepatology. 2018;67:422–35.PubMed

96.

Huo YR, Eslick GD. Transcatheter arterial chemoembolization plus radiotherapy compared with chemoembolization alone for hepatocellular carcinoma: a systematic review and meta-analysis. JAMA Oncol. 2015;1:756–65.PubMed

97.

Yoon SM, Ryoo BY, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol. 2018.

98.

•• Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–36 Randomized controlled trial comparing sorafenib and TARE for BCLC-C patients demonstrating no difference in overall survival but reduced side effects with TARE (see text for discussion).PubMed

99.

•• Chow PKH, Gandhi M, Tan S-B, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol Off J Am Soc Clin Oncol. 2018;JCO2017760892. Randomized controlled trial comparing sorafenib and TARE for BCLC-C patients demonstrating no difference in overall survival but reduced side effects with TARE (see text for discussion).

100.

Hermann A-L, Dieudonné A, Maxime R, et al. PS-018 - role of 99mTc-macroaggregated albumin SPECT/CT based dosimetry in predicting survival and tumor response of patients with locally advanced and inoperable hepatocellular carcinoma (HCC) treated by selective intra-arterial radiation therapy (SIRT) with yttrium-90 resin microspheres, a cohort from SARAH study. J Hepatol. 2018;68:S13.

101.

AbdelRazek M, Khalaf M, Abdelmaksoud M, et al. 3:27 PM abstract no. 124 MIRD-based activity calculation may improve outcomes over body surface area for resin microsphere radioembolization of metastatic colorectal carcinoma. J Vasc Interv Radiol. 2018;29(4):S56.

102.

Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology. 2018;67:381–400.PubMed

103.

Parikh ND, Waljee AK, Singal AG. Downstaging hepatocellular carcinoma: a systematic review and pooled analysis. Liver Transplant Off Publ Am Assoc Study Liver Dis Int Liver Transplant Soc. 2015;21(9):1142–52.

104.

Otto G, Herber S, Heise M, et al. Response to transarterial chemoembolization as a biological selection criterion for liver transplantation in hepatocellular carcinoma. Liver Transpl. 2006;12:1260–7.PubMed

Title: Indications and Best Practices for Intra-arterial Therapies to Treat Hepatocellular Carcinoma
Authors: Michael Hsu
Muneeb Ahmed
Ammar Sarwar
Publication date: 01-12-2018
Publisher: Springer US
Published in: Current Hepatology Reports / Issue 4/2018
Electronic ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-018-0428-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Indications and Best Practices for Intra-arterial Therapies to Treat Hepatocellular Carcinoma

Abstract

Purpose of Review

Recent Findings

Summary

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2018

Implications of Circulating Hepatitis B Virus RNA Levels in Assessment of Response to Antiviral Therapy

Hepatitis B Reactivation in the DAA Era: Minding the Gap Between the Black Box and Clinical Practice

Prevention and Management of HBV Infection in Patients with Chronic Kidney Disease Requiring Renal Transplantation

Long-term Outcomes in Patients with HBV Treated with Antiviral Agents

Impact of Chronic Hepatitis B Infection on Patient-Reported Outcomes

Small Esophageal Varices in Patients with Cirrhosis—Should We Treat Them?

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page